SNPHY (Santen Pharmaceutical Co) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 25, 2026)


SNPHY Santen Pharmaceutical Co Ltd SNPHY
87 GF Score
Price $12.36
GF Value $10.15
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Santen Pharmaceutical Co Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Santen Pharmaceutical Co's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

SNPHY vs LLY, JNJ, ABBV: Margin of Safety % (DCF FCF Based) Comparison

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Santen Pharmaceutical Co Margin of Safety % (DCF FCF Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Margin of Safety % (DCF FCF Based) falls into.


SNPHY
87GF Score
Santen Pharmaceutical Co Ltd SNPHY
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Santen Pharmaceutical Co (SNPHY) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of $12.36 is trading 21.8% above its estimated GF Value™ of $10.15. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SNPHY:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $10.15 vs. price of $12.36 (21.8% above fair value)
  • GF Score™: 87/100 with 6 warning signs

No single metric tells the full story. See the SNPHY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santen Pharmaceutical Co Business Description

Other Exchanges 4536:Japan
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
87GF Score

Get the complete analysis for SNPHY

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.36
Price
$10.15
GF Value